| Identification | Back Directory | [Name]
1,4-Benzodioxin-6-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-2,3-dihydro-8-methoxy- | [CAS]
931078-17-0 | [Synonyms]
CPI905
CPI-905
CPI 905
1,4-Benzodioxin-6-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-2,3-dihydro-8-methoxy- | [Molecular Formula]
C18H20N2O5 | [MDL Number]
MFCD09360203 | [MOL File]
931078-17-0.mol | [Molecular Weight]
344.36 |
| Hazard Information | Back Directory | [Description]
CPI-905 is a potent and selective EZH2 inhibitor (IC50 = 39.5 nM). The histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an oncogenic driver in a subset of germinal center B-celllike diffuse large B cell lymphoma (GCB-DLBCL) and follicular lymphoma due to the presence of recurrent, monoallelic mutations in the EZH2 catalytic domain. . | [Uses]
CPI-905 is a potent, selective, and cell-active EZH2 inhibitor[1]. | [References]
[1] William D Bradley, et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014 Nov 20;21(11):1463-75. DOI:10.1016/j.chembiol.2014.09.017 |
|
|